Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to equity ratio is 0.00 as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
0.00
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 512 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Coya Therapeutics, Inc.
Market Cap
$112.36M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$113.17M
Debt to Equity Ratio
2.28
TTM Avg
3.15
3Y Avg
2.13
5Y Avg
1.28
Market Cap
$109.91M
Debt to Equity Ratio
3.72
TTM Avg
2.72
3Y Avg
1.72
5Y Avg
1.15
Market Cap
$109.20M
Debt to Equity Ratio
0.01
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$108.33M
Debt to Equity Ratio
N/A
TTM Avg
230.24
3Y Avg
153.68
5Y Avg
153.68
Market Cap
$116.08M
Debt to Equity Ratio
N/A
TTM Avg
0.12
3Y Avg
0.14
5Y Avg
0.21
Market Cap
$116.53M
Debt to Equity Ratio
0.15
TTM Avg
0.11
3Y Avg
0.12
5Y Avg
0.12
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $112.36M | 0.00 | 0.00 | 0.00 | 0.00 |
| BGM Group Ltd. (BGM)vs › | $111.84M | 0.00 | 0.00 | 0.01 | 0.08 |
| Lucid Diagnostics Inc. (LUCD)vs › | $113.17M | 2.28 | 3.15 | 2.13 | 1.28 |
| Apyx Medical Corporation (APYX)vs › | $109.91M | 3.72 | 2.72 | 1.72 | 1.15 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.20M | 0.01 | 0.00 | 0.00 | 0.00 |
| MaxCyte, Inc. (MXCT)vs › | $115.52M | 0.11 | 0.10 | 0.08 | 0.09 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $108.33M | N/A | 230.24 | 153.68 | 153.68 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.08M | N/A | 0.12 | 0.14 | 0.21 |
| Genelux Corporation (GNLX)vs › | $116.53M | 0.15 | 0.11 | 0.12 | 0.12 |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.04M | 0.27 | 0.16 | 0.12 | 0.10 |
Debt/Equity
0.00
Current Ratio
13.40
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | -1.54 |
| 2022-09-30 | -2.21 |
| 2022-06-30 | -7.43 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
